• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Nanobiotechnology . Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope

tetano

Editor, Senior Moderator
J Nanobiotechnology


. 2025 Feb 4;23(1):77.
doi: 10.1186/s12951-025-03122-6. Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine

Yongqiang Zhao[SUP] 1 [/SUP], Jia Liu[SUP] 1 [/SUP], Chun Peng[SUP] 2 [/SUP], Shuangshuang Guo[SUP] 3 [/SUP], Bo Wang[SUP] 3 [/SUP], Longping Chen[SUP] 3 [/SUP], Yating Wang[SUP] 1 [/SUP], Haiwen Tang[SUP] 2 [/SUP], Liming Liu[SUP] 4 [/SUP], Qi Pan[SUP] 4 [/SUP], Shiren Li[SUP] 2 [/SUP], Jingyu Wang[SUP] 1 [/SUP], Dongni Yang[SUP] 5 [/SUP], Enqi Du[SUP] 6 7 [/SUP]



Affiliations
Abstract

Background: Influenza A viruses (IAVs) cause seasonal influenza epidemics and pose significant threats to public health. However, seasonal influenza vaccines often elicit strain-specific immune responses and confer little protection against mismatched strains. There is an urgent need to develop universal influenza vaccines against emerging and potentially re-emerging influenza virus infections. Multiepitope vaccines combining multiple conserved epitopes can induce more robust and broader immune responses and provide a potential solution.
Results: Here, we demonstrated that an HA chimeric multiepitope nanoparticle vaccine, delivered intranasally conferred broad protection against challenges with various influenza viruses in mice. The nanoparticle vaccine co-expresses the ectodomain of haemagglutinin (H), three repeated highly conserved ectodomains of matrix protein 2 (M), and the M-cell-targeting ligand Co4B (C) in a baculovirus-insect cell system. These elements (C, H and M) were presented on the surface of self-assembling ferritin (f) in tandem to generate a nanoparticle denoted as CHM-f. Intranasal vaccination with CHM-f nanoparticles elicited robust humoral and cellular immune responses, conferring complete protection against a variety of IAVs, including the A/PR8/34 H1N1 strain, the swine flu H3N2 strain, the avian flu H5N8 strain, and H9N2. When CHM-f nanoparticles adjuvanted with CpG IAMA-002, the weight loss protective effect, cellular immune responses and mucosal IgA responses were significantly augmented. Compared with controls, mice immunized with CHM-f nanoparticles with or without CpG IAMA-002 showed significant reductions in weight loss, lung viral titres and pathological changes.
Conclusions: These results suggest that CHM-f nanoparticle with or without CpG IAMA-002 is a promising candidate as a universal influenza vaccine.

Keywords: Cross-protection; Influenza virus; Nanoparticle vaccine; Universal influenza vaccine.

 
Back
Top Bottom